Franco Moro, CEO & COO – Stevanato Group
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
MolMed S.p.A. is a medical biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes anti-tumour therapeutics in clinical and preclinical development: Zalmoxis® (TK) is a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, currently in Phase III in high-risk acute leukaemia and under evaluation by EMA for a Conditional Marketing Authorization; NGR-hTNF is a novel therapeutic agent for solid tumours which displays antitumor activity through its specific binding to blood vessels feeding the cancer and to the concentration of immune system cells into the tumour mass, currently investigated in a broad clinical programme, involving more than 1000 treated patients; CAR-CD44v6, an immuno-gene therapy project potentially effective for many haematological malignancies and several epithelial tumours, currently in preclinical development. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed has its headquartered at the San Raffaele Biotechnology Department (DIBIT) in Milan, Italy, and a local unit at OpenZone, in Bresso (Milan). MolMed is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana (ticker Reuters: MLMD.MI).
Contact
MolMed S.p.A.
Via Olgettina, 58
20132 Milano, Italy
Tel.+39 02 21277.1
Fax +39 02 21277.325
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time…
Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges…
Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of…
Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic…
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Ferring Pharmaceuticals’ Federico Gomes de Freitas, General Manager Italy, gives us an overview of how the Italian affiliate fits into the company’s global strategy, especially with respect to reproductive health,…
Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous…
Giorgio Palú, President of the Italian Medicines Agency (AIFA) helps us understand how the agency works, explains the criteria they use to evaluate innovative medicines and tells us about AIFA’s…
Medac Pharma Italy’s Giovanni Sala describes the Italian affiliate’s unique portfolio of haematology, onco-urology, and neurosurgery products, as well as generics, and outlines the challenges of the Italian market. …
SIFI’s Fabrizio Chines outlines how the company is progressing in European ophthalmic markets, explains the added value it is bringing to the glaucoma field, and tells us about its orphan drug…
Massimo Scaccabarozzi, President of Farmindustria, discusses Italy’s response to the pandemic and the association’s key priorities, which include maintaining Italy’s position as a European leader in terms of production. Italy…
See our Cookie Privacy Policy Here
